MPI für molekulare Genetik / Department of Human Molecular Genetics |
|Point mutations in GLI3 lead to misregulation of its subcellular localization|
|Authors:||Krauß, Sybille; So, Joyce; Hambrock, Melanie; Köhler, Andrea; Kunath, Melanie; Scharff, Constance; Wessling, Martina; Grzeschik, Karl-Heinz; Schneider, Rainer; Schweiger, Susann|
|Date of Publication (YYYY-MM-DD):||2009-10-15|
|Title of Journal:||PLoS ONE|
|Copyright:||© 2009 Krauß et al|
|Review Status:||not specified|
|Abstract / Description:||Background
Mutations in the transcription factor GLI3, a downstream target of Sonic Hedgehog (SHH) signaling, are responsible for the development of malformation syndromes such as Greig-cephalopolysyndactyly-syndrome (GCPS), or Pallister-Hall-syndrome (PHS). Mutations that lead to loss of function of the protein and to haploinsufficiency cause GCPS, while truncating mutations that result in constitutive repressor function of GLI3 lead to PHS. As an exception, some point mutations in the C-terminal part of GLI3 observed in GCPS patients have so far not been linked to loss of function. We have shown recently that protein phosphatase 2A (PP2A) regulates the nuclear localization and transcriptional activity a of GLI3 function.
We have shown recently that protein phosphatase 2A (PP2A) and the ubiquitin ligase MID1 regulate the nuclear localization and transcriptional activity of GLI3. Here we show mapping of the functional interaction between the MID1-α4-PP2A complex and GLI3 to a region between amino acid 568-1100 of GLI3. Furthermore we demonstrate that GCPS-associated point mutations, that are located in that region, lead to misregulation of the nuclear GLI3-localization and transcriptional activity. GLI3 phosphorylation itself however appears independent of its localization and remains untouched by either of the point mutations and by PP2A-activity, which suggests involvement of an as yet unknown GLI3 interaction partner, the phosphorylation status of which is regulated by PP2A activity, in the control of GLI3 subcellular localization and activity.
The present findings provide an explanation for the pathogenesis of GCPS in patients carrying C-terminal point mutations, and close the gap in our understanding of how GLI3-genotypes give rise to particular phenotypes. Furthermore, they provide a molecular explanation for the phenotypic overlap between Opitz syndrome patients with dysregulated PP2A-activity and syndromes caused by GLI3-mutations.
|Comment of the Author/Creator:||email: email@example.com|
|External Publication Status:||published|
|Version Comment:||Automatic journal name synchronization|
|Communicated by:||Hans-Hilger Ropers|
|Affiliations:||MPI für molekulare Genetik|
|External Affiliations:||Charité University Hospital, Department of Dermatology, Berlin, Germany
Institute of Biochemistry and Center for Molecular Biosciences Innsbruck (CMBI), Innsbruck, Austria
Center for Human Genetics, Phillipps University, Marburg, Germany
Ninewells Hospital, Department of Neuroscience and Pathology, Dundee, United Kingdom
The scope and number of records on eDoc is subject
to the collection policies defined by each institute
- see "info" button in the collection browse view.